Jiangsu Key Laboratory of Marine Pharmaceutical Compound Screening, College of Pharmacy, Jiangsu Ocean University, Lianyungang, 222005, China.
Department of Pathology, The Second People's Hospital of Lianyungang, 41 Hailian East Road, Haizhou, Lianyungang, 222006, Jiangsu, PR China.
Cell Death Dis. 2023 Feb 4;14(2):83. doi: 10.1038/s41419-023-05588-4.
SEMA6A is a multifunctional transmembrane semaphorin protein that participates in various cellular processes, including axon guidance, cell migration, and cancer progression. However, the role of SEMA6A in clear cell renal cell carcinoma (ccRCC) is unclear. Based on high-throughput sequencing data, here we report that SEMA6A is a novel target gene of the VHL-HIF-2α axis and overexpressed in ccRCC. Chromatin immunoprecipitation and reporter assays revealed that HIF-2α directly activated SEMA6A transcription in hypoxic ccRCC cells. Wnt/β-catenin pathway activation is correlated with the expression of SEMA6A in ccRCC; the latter physically interacted with SEC62 and promoted ccRCC progression through SEC62-dependent β-catenin stabilization and activation. Depletion of SEMA6A impaired HIF-2α-induced Wnt/β-catenin pathway activation and led to defective ccRCC cell proliferation both in vitro and in vivo. SEMA6A overexpression promoted the malignant phenotypes of ccRCC, which was reversed by SEC62 depletion. Collectively, this study revealed a potential role for VHL-HIF-2α-SEMA6A-SEC62 axis in the activation of Wnt/β-catenin pathway. Thus, SEMA6A may act as a potential therapeutic target, especially in VHL-deficient ccRCC.
SEMA6A 是一种多功能跨膜信号蛋白,参与多种细胞过程,包括轴突导向、细胞迁移和癌症进展。然而,SEMA6A 在透明细胞肾细胞癌(ccRCC)中的作用尚不清楚。基于高通量测序数据,我们在这里报道 SEMA6A 是 VHL-HIF-2α 轴的一个新的靶基因,在 ccRCC 中过表达。染色质免疫沉淀和报告基因检测显示,HIF-2α 在低氧 ccRCC 细胞中直接激活 SEMA6A 的转录。Wnt/β-catenin 通路的激活与 ccRCC 中 SEMA6A 的表达相关;后者与 SEC62 相互作用,并通过 SEC62 依赖的 β-catenin 稳定和激活促进 ccRCC 进展。SEMA6A 的缺失削弱了 HIF-2α 诱导的 Wnt/β-catenin 通路激活,并导致体外和体内 ccRCC 细胞增殖缺陷。SEMA6A 的过表达促进了 ccRCC 的恶性表型,而 SEC62 的缺失则逆转了这一现象。总之,本研究揭示了 VHL-HIF-2α-SEMA6A-SEC62 轴在 Wnt/β-catenin 通路激活中的潜在作用。因此,SEMA6A 可能是一个潜在的治疗靶点,特别是在 VHL 缺陷型 ccRCC 中。